Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12202119 | 0.92 | ALDH1A1 (0.68) | ALDH1A1PDE10APOLBNPC1RAB9A | |
| SCHEMBL14332366 | 0.82 | ALDH1A1 (0.86) | ALDH1A1GAAMAPT | |
| SCHEMBL4788011 | 0.80 | ALDH1A1 (0.62) | ALDH1A1PDE10A | |
| SCHEMBL17525710 | 0.80 | POLB (0.54) | PDE10APOLBEGLN3NPC1RAB9A | |
| SCHEMBL7475210 | 0.80 | PDE10A (0.48) | ALDH1A1PDE10APOLBNPC1RAB9A | |
| SCHEMBL8327859 | 0.79 | ALDH1A1 (0.64) | ALDH1A1 | |
| SCHEMBL230157 | 0.77 | POLB (0.84) | PDE10APOLBNPC1RAB9ACHRM1 | |
| SCHEMBL1115713 | 0.77 | ALDH1A1 (0.55) | ALDH1A1PDE10APOLBCYP2D6CYP2C19 | |
| SCHEMBL7479144 | 0.76 | GAA (0.46) | ALDH1A1PDE10ANPC1RAB9AMEN1 | |
| SCHEMBL5509427 | 0.74 | PDE10A (0.84) | ALDH1A1PDE10APOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984642-B1 | Substituted phenylcyclohexane carboxylic acid amides and their use as adenosine uptake inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2006-01-10 | — | — | US | disclosed |
| EP-1187812-B1 | SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THEIR USE AS ADENOSINE UPTAKE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20040186106-A1 | Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect | BAYER HEALTHCARE AG (DE) | 2004-09-23 | — | — | US | disclosed |
| US-6716849-B1 | ISCHEMIC BRAIN DISORDERS; NEUROPROTECTANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-06 | — | — | US | disclosed |
| EP-1185516-B1 | SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES THAT HAVE AN ADENOSINE UPTAKE INHIBITING EFFECT | BAYER AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| EP-1187812-A2 | SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THEIR USE AS ADENOSINE UPTAKE INHIBITORS | Bayer Aktiengesellschaft (DE) | 2002-03-20 | — | — | EP | disclosed |
| EP-1185516-A1 | SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES THAT HAVE AN ADENOSINE UPTAKE INHIBITING EFFECT | Bayer Aktiengesellschaft (DE) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000073274-A2 | SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES AND THEIR USE AS ADENOSINE UPTAKE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000073275-A1 | SUBSTITUTED PHENYLCYCLOHEXANE CARBOXYLIC ACID AMIDES THAT HAVE AN ADENOSINE UPTAKE INHIBITING EFFECT | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186106-A1 | Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect | ADORA1, ADORA2A, ADORA3 | ALDH1A1 312/4885PDE10A 403/4885POLB 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.